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Abstract 
Baculovirus has been a common tool for protein production since the mid 1980s.  
The virus has an exclusive tropism only capable of infecting the larval stages of insects.  
Originally, baculovirus recombinant gene expression used Spodoptera frugiperda (Sf9) insect 
cells   as the host cells for protein production.  However, in 1995, it was discovered that 
baculoviruses could be modified to transduce mammalian cells with the insertion of a 
mammalian promoter and gene of interest.  Due to its ease of generation and low biology safety 
hazards, this technology, known as BacMam (Baculovirus Mammalian) is popular in the research 
field for protein production and for cell based and membrane binding drug discovery assays.  
BacMam viruses have shown high transduction efficiencies in many widely used mammalian cell 
lines such as CHO-K1, HEK293F, and U-2 OS cells.  However, some cancer cell lines do not 
transduce well.  Because disease relevant cell lines are preferred in cell based assays, we want 
to increase the transduction efficiencies in these lines.  Pseudotyping, a way of modifying the 
wild type envelope protein to enhance target specificity, could be a method of increasing 
efficiencies.  We have generated four pseudotyping viruses using the Vesicular Stomatitis Virus 
glycoprotein (VSV-G).  
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CHAPTER 1: Introduction 
 
Baculovirus 
The Baculoviridae are a family of rod shaped enveloped viruses whose tropism is 
limited to invertebrates, mainly insects. First observed when it distressed the silk 
industry in the 1500s, baculovirus technology has evolved into a major biotechnology 
tool for recombinant protein expression. Its genome, composed of circular double 
stranded DNA, can range anywhere between 80kb-180 kb in size45. The family is divided 
into two genera:  nucleopolyhedroviruses (NPVs) and granuloviruses (GVs), so named 
for their morphology and their method of enveloping the nucleocapsids in infected 
cells22. GVs generate occlusion bodies much smaller than those of NPVs (about 0.3 µm 
in diameter and 1.5 µm respectively) and NPVs are encapsulated in polyhedrin protein 
and GVs in granulin.  An occlusion body is the crystalline protein matrix surrounding the 
nucleocapsids of the virion. Occlusion derived viruses have evolved to protect the virus 
from extinction during winter months when their hosts may die.  Under normal weather 
conditions, save extreme heat or UV light,  they can remain viable indefinitely38. The 
crystalline matrices also can survive avian digestive systems facilitating distribution to 
insect hosts15.   Another difference in NPVs and GVs are their hosts, with GVs only 
infecting leptidopteran (butterflies and moths) species and NPVs possessing a broader 
tropism for other insects including flies and butterflies. 
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The most common baculovirus utilized in our laboratory is an NPV and further 
discussion will involve only NPVs. Leptidopteran infecting NPVs have been divided into 
two groups of NPVs: Group I and II based on molecular phylogenies50.  NPVs can be 
further subdivided by the number of nucleocapsids within the occlusion body’s virus 
envelope. Those with a single nucleocapsid per envelope are called single 
nucleopolyhedroviruses (SNPVs), whereas those with multiple nucleocapsids in each 
envelope are called multiple nucleopolyhedroviruses (MNPVs)38.  Baculoviruses are 
usually named for the host that they were isolated from initially and their 
classification38. For example, the Plutella xylostella nucleopolyhedrovirus (PlxyNPV) was 
first observed in the Plutella xylostella (diamondback moth) and it is a SNPV. The species 
of baculovirus that is used in this laboratory is the Autographa californica multiple 
nucleopolyhedrovirus (AcMNPV). Found originally in Autographa californica (alfalfa 
looper), it contains multiple nucleocapsids in each envelope.     
Baculoviruses produce two types of virions: occluded derived (ODVs) and 
budded viruses (BVs) (Figure 1). Occluded viruses (inside its crystalline matrix) initiate 
viral infection while budded viruses are responsible for secondary cycles of infection. 
The genome is identical, but there are key differences between the two.  In Group I 
NPVs, the BVs contain the glycoprotein GP64 while Group II NPVs (and also GVs) contain 
the F-protein (also known as Ld130) found at one end of the virion on projections called 
peplomers33,47.  Glycoproteins are responsible for viral attachment and membrane 
fusion entry into the host5. AcMNPV is a Group I NPV. ODVs do not contain GP64 (or F-
protein) but have their own virus encoded envelope protein, P74, without 
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peplomers26,47. ODVs obtain their envelope in the nucleus of the host cell while BVs 
acquire their envelope from budding through the plasma membrane5,9. In MNPVs, ODVs 
contain multiple nucleocapsids whereas BVs contain a single nucleocapsid per 
envelope47.  
 
Figure 1:  Images of Budded virus and Occluded derived virus in AcMNPV.  BVs contain 
one nucleocapsid with GP64 protruding from peplomers at head of virion. The envelope 
is derived from the host’s plasma membrane. ODVs contain multiple nucleocapsids per 
envelope and are surrounded by a crystalline matrix of polyhedrin. The envelope is 
derived from intranuclear microvesicles in the host’s nucleus8.  
Source: http://www.microbiologybytes.com/virology/kalmakoff/baculo/baculo.html 
 
Replication of Baculovirus in vivo 
Baculoviruses have a biphasic cycle of replication where both BVs and ODVs are 
produced5,22. Initial infection occurs when an insect ingests occlusion bodies (OBs) 
where the polyhedra matrix is dissolved by the alkaline midgut of the host releasing 
infectious ODV.  ODVs infect the gut epithelial cells by direct membrane fusion20.  In 
several hours, infected cells become enlarged as the viral DNA replication and 
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nucleocapsid assembly occurs in the nucleus4.  After assembly, nucleocapsids bud in 
regions where GP64 has localized on the host’s plasma membrane generating progeny 
BVs which exit the basal membrane into the hemolymph of the host22. From there, the 
infection spreads primarily through the tracheal system14.  In the late phase, 
nucleocapsids no longer bud, but become enveloped in the host’s nucleus to create 
more OBs9. Due to infection, the host dies and liquefies releasing the OBs into the 
environment38.  Liquefaction occurs by virus-encoded production of chitinase and 
cathepsin18.  
GP64 
GP64 is the major glycoprotein in AcMNPV BV.  It is necessary for low pH 
triggered membrane fusion5.  However, it has also been shown to be necessary for 
budding of the nucleocapsids for propagation of BV.  Knock-out gp64 (gp64-) viruses 
have shown that GP64 is necessary for efficient virion budding from host’s plasma 
membrane.  In order to produce virus for the study, gp64- baculovirus was generated 
using a stably transfected cell line supplying the GP64 protein32.  Virion proliferation was 
essentially eliminated in gp64- baculovirus. This indicates that cell to cell transmission 
was halted due to lack of budding, not the inability to mediate membrane fusion32.  
AcMNPV in biotechnology 
There are many reasons that baculoviruses have become a valuable 
biotechnology research tool.  Because of their exclusive tropism, the biosafety 
considerations of baculovirus are low and these viruses can be handled with little 
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concern24. In addition, baculoviruses possess the same protein modification traits in 
prokaryotic cell processing and transport systems as viruses infecting higher eukaryotic 
cells22. This makes them a significant asset to research. 
In nature, AcMNPVs infect insects. But in the 1970s researchers  began 
investigating the virus and were able to replicate the virus in vitro in insect cell lines, 
particularly Trichoplusia ni (Tni) and Spodoptera frugiperda (Sf9 or Sf21) 46. For the next 
decade, molecular biologists worked on modifying the viral genome.   They found that it 
was possible to delete the very late polyhedrin gene (with no consequences) and insert 
other genes of interest to be driven by its very strong polyhedrin promoter and express 
it in Tni or Sf9/Sf21 cell lines43.   The deletion of the polyhedrin gene causes the 
production of only BV42.   In 1994,  Ayers et al. published the AcMNPV genome, 
beginning a new era in molecular biology and baculovirus studies2.  Soon after, the 
BacMid system, a site-specific transposon-mediated insertion method,  was introduced 
to facilitate production of recombinant protein in the AcMNPV genome27. The name 
pFastBac is used to describe traditional baculovirus transfer vectors with transposon 
sites.   Before the BacMid system was developed, scientists had to visually select 
plaques, in a virus titration,  that were polyhedra negative to identify their modified 
virus16.   The use of baculovirus expression vectors are still widely used in academic and 
industry today.  
BacMam technology 
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In the mid 1990’s, two groups reported efficient transduction of mammalian 
cells using a cytomegalovirus (CMV) promoter and luciferase reporter gene and using a  
Rous sarcoma virus (RSV) promoter with β-galactosidase as the reporter6,19. 
Hoffman et al. showed that by replacing the polyhedrin promoter with the 
mammalian CMV immediate early promoter directly fused to luciferase in a baculovirus 
transfer vector efficiently transduced human hepatocytes19.  A baculovirus transfer 
vector contains recombination sites flanking the modified region for homologous 
recombination into the polyhedrin region of AcMNPV (BacMid technology)34.  With 
treatment of their modified baculovirus, called AcNPV-CMV, human and rabbit 
hepatocytes displayed expression of luciferase showing efficient gene delivery to two 
mammalian cell lines.  
 Boyce and Bucher excised an RSV-lacZ cassette from a holding vector and 
inserted it into an AcMNPV transfer vector with additional splice and polyadenylation 
sequences from simian virus 40 (SV40) to include RNA processing signals6. At the time, 
RSV had already been known to show strong expression in mammalian cells.   
β-galactosidase enzyme activity was used to measure transduction efficiency in various 
cell lines.   As with Hoffman et al., this group showed high efficiency of transduction in 
human hepatocytes.  However, when other human cell lines were transduced, efficiency 
was low.  Because cell lines expressing high and low quantities of reporter protein were 
shown to internalize comparable amounts of virus, lack of expression was believed to 
due to a downstream effect6. Later, another group determined that under control of the 
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CAG promoter (a hybrid promoter consisting of CMV immediate early enhancer, chicken 
β-actin promoter and rabbit β-globin polyadenylation sequence), many of those cell 
lines were able to express the reporter protein41.  These experiments also showed that 
the baculovirus was not replicating in mammalian cell lines, therefore expression was 
via transduction and not infection40. Soon baculovirus was able to transduce a wide 
variety of mammalian cell lines. In our company, this modified baculovirus system is 
now called BacMam (Baculovirus Mammalian), and will be described as such in the rest 
of this manuscript to avoid confusion.  
As this technology has developed it was discovered that the genome is able to 
hold up to 38 kb of insert, making it possible to insert large or multiple genes into the 
virus17,24.  The versatility of this gene delivery tool has made it popular in the research 
field for protein production and for cell based and membrane binding drug discovery 
assays.  BacMam transduction is often used in place of stable cell lines due to its ease of 
generation, its ability to save time, as well its low biological hazards24. Production of 
stable cell lines is slow, laborious, and time consuming and BacMam generation takes 
considerably less time 35.  In order to express two genes in a stable cell line it will take 
twice the amount of time to produce the transfectant. In contrast, a co-expression of 
genes using BacMams is simply a co-transduction of the two BacMam viruses together 
8 
 
 
and is sufficient for expression of many genes in most cases (Figure 2).
 
Figure 2: Schematic showing co-transduction using two BacMam viruses. With 
the correct ratio of each virus, it is possible to obtain cells expressing both genes X and 
Y.  
BacMam is generally safer than other viral vectors such as adenovirus or 
lentivirus that have the ability to replicate in humans7.  Because of adenovirus and 
lentivirus’ infectivity, their biological safety considerations are much higher than that of 
BacMam and must be handled with caution in the lab17.  Also,  because the polyhedrin 
promoter has been deleted from the vector, these viruses are unable to replicate in 
insect larvae making them environmentally safe31. For these reasons, BacMam is the 
preferred method for gene expression for mammalian cells at GlaxoSmithKline.  
BacMam has been proven effective in a plethora of mammalian cell types 
including HEK 293(human embryonic kidney), CHO (Chinese Hamster Ovary), U2-
OS(human osteosarcoma)1,13,25,29, HeLa(human cervical carcinoma)13, HepG2 
(hepatocytes)6,19 and Pancreatic B cells28. Some cell lines may require a higher 
multiplicity of transduction (MOT) for effective transduction but they are still 
transduceable.  Even at a high MOT, BacMam virus is not toxic to mammalian cells, 
however it has been found that high volumes of insect media(conditioned insect media 
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is the preferred storage of BacMam) can be toxic to cells. This can be avoided by 
concentrating virus using a sucrose cushion19.  Although the effectiveness of BacMam 
has been shown in many cell lines, some are more difficult to transduce. Although not 
the case for all, efficiency can be enhanced in most cell lines using histone deacetylase 
(HDAC) inhibitors such as trichostatin A or sodium butyrate13. These HDAC inhibitors 
cause a hyperacetylation of the chromatin for augmentation of transcription. The 
markedly increased transduction can be visualized using a reporter gene BacMam such 
as Green Fluorescence Protein (GFP) under control of the CMV promoter. At a 
wavelength 509 nm, GFP will fluoresce demonstrating successful uptake of the virus by 
the cell.  Condreay et al. found that out of 20 cell lines tested, 18 were enhanced by 
addition of 10 mM Sodium Butyrate 24 hours after treatment with BacMam-GFP.  
However, addition of HDAC inhibitors can have a toxic effect48. In our hands, 
concentrations above 20 mM Sodium Butyrate can be significantly detrimental to most 
mammalian cell lines (as shown by hemocytometer count)35. We began looking for 
other ways to enhance expression in difficult to transduce cell lines.  
Pseudotyping 
Recently, our colleagues have been interested in using some cell lines that are 
not effectively transduced by BacMam. The need is due to the physiological importance 
of these lines in the diseases being investigated. For example, an Oncology team looking 
for breast cancer treatments requests a screen in SKBR3, human breast adenocarcinoma 
cells, a line most relevant to the disease. This is an example of a line that hasn’t been 
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transduceable using BacMam with current available treatments. This led to looking into 
pseudotyping BacMam virus. Pseudotyping is a general term for structural proteins  
contained within a virus particle but not encoded by the viral genome39. In this case, and 
most commonly, this involves introducing a foreign glycoprotein from another virus into 
our original host vector.  We have chosen to introduce Vesicular Stomatitis Virus 
glycoprotein (VSV-G) into our BacMam vector.  
VSV-G 
Vesicular Stomatitis Virus (VSV) is in the family Rhabdoviridae and has tropism 
for both mammalian and insect cells37.  Its glycoprotein (VSV-G) is one of the most highly 
used pseudotyping tools today.  Originally, it was used for pseudotyping retroviruses 
because of its large target range10. It has also been shown to increase Baculovirus 
transduction efficiency by 10 to 100 fold greater than baculovirus without VSV-G3. In 
addition to VSV’s wide tropism, it also has the capability to increase efficiency by 
increasing the amount of glycoprotein on the surface of the virus envelope44.  GP64 is 
situated at the peplomers on the head of the virion but VSV-G is found around the 
entire envelope (Figure 3). 
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Figure 3: Schematic showing enhancement of glycoproteins in VSV-G pseudotyped 
BacMam. Figure A shows regular virus where gp64 sits on the head of the virion and 
carries GFP (green circle). Figure B shows BacMam with VSV-G which covers the virion 
increasing GFP expression opportunity simply by quantity of glycoprotein.  
 
 In addition to pseudotyping using native VSV-G, it has also been found that a 
truncated version containing 42 amino acids of VSV-G ectodomain (ECD) plus the 
transmemembrane domain (TM) and C terminal domain (CTD) of VSV-G can effectively 
increase transduction levels36.  Kaikkonen et al. found an increase in efficiency of 
baculovirus pseudotyped with truncated VSV-G21. Because of these observations, we 
have designed a set of pseudotyping BacMams for analysis.  These include the truncated 
version of VSV-G and the full length version in a GFP reporter construct. In addition both 
truncated and full length versions will be inserted into standard Baculovirus transfer 
vectors.  
Hypothesis:  
Disease relevant cell lines are preferred over current cell lines due to their ability 
to closely mimic in vivo conditions. BacMam transduction efficiency in these cell lines is 
low. It is hypothesized that pseudotyped BacMams may deliver genes to these cell lines 
more efficiently than standard BacMam. 
Specific Aims:   
Specifically, I will generate four different BacMam/baculoviruses that will be 
used in the future to transduce disease-relevant cell lines that have historically low 
transduction efficiencies:  
12 
 
 
BacMam Vectors: 
 pCMVDual-ZsGreen- VSV-G truncate- BacMam vector containing both CMV 
promoter driving ZsGreen, a GFP reporter protein,  as well the polyhedrin promoter 
driving a truncated version of VSV-G. 
 pCMVDual-ZsGreen- VSV-G Full Length- Same as construct above with 
polyhedrin driving the Full Length VSV-G.  
Baculovirus Vectors:  
  pFastBac-VSV-G truncate- A traditional baculovirus vector with only the insect 
specific polyhedrin promoter and no reporter gene present. In this construct, polyhedrin 
is driving the truncated version of VSV-G.  
  pFastBac-VSV-G Full Length- Same as above with polyhedrin driving Full Length 
VSV-G.  
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CHAPTER 2: Methods and Materials 
Design of truncated VSV-G  
The synthetic VSV-G was designed and ordered from the company IDT 
(Coralville, IA) in the holding vector pZero2. The truncated VSV-G contained gp64 signal 
sequence, a multiple cloning site, a twenty alanine spacer, and the ectodomain, 
transmembrane domain and C-terminal domain of VSV-G.  This was flanked by 
restriction sites BamHI/XbaI to facilitate extraction of VSV-G by restriction digest. 
 
PCR amplification of truncated VSV-G from its holding vector for pFastBac 
Because of issues with the IDT product and resultant band size of cut truncated 
VSV-G, PCR amplification was necessary to obtain the correct sequence from the 
backbone vector pZero2. Sequence specific forward (5’ CAT CGG GCG CGG ATC CAC CAT 
GGT GTC CGC CAT CGT GCT GTA CGT GCT G) and reverse (GAC TGC AGG CTC TAG ATC 
ACT TGC CCA GGC GGT TCA TCT CGA TGT CGG TGT AGA TC 5’) primers were purchased 
from IDT.  In design, the oligos also introduced a 10 base pair homology with pFastBac (a 
baculovirus transfer vector) and pCMVDual-ZsGreen (a BacMam transfer vector) for 
subsequent steps in generation of final transfer vectors.  In order to ensure high quality 
polymerase activity, three high fidelity polymerases PFU Herculase, PFU Turbo, and PFU 
Ultra, (Agilent, Santa Clara, CA) were used in the PCR amplification reaction.  Forward 
and reverse primers, pZero2/VSV-G (template DNA), DNTPs, PFU buffer and PFU 
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polymerase were combined (one tube for each polymerase) and run in the BioRad DNA 
Engine Peltier Thermal Cycler using the PCR amplification program (Settings Figure 4).  
Due to the sequence homology to final vectors pCMVDual-ZsGreen and pFastBac (the 
homology is the same for both vectors), the PCR product could be used for insertion of 
VSV-G into the vectors. 
 
Figure 4: PCR amplification reaction cycle 
 
PCR amplification of VSV-G full length (FL) from its holding vector 
Fortunately, the template sequence for full length VSV-G was archived in our in-
house depository.  For continuity, PCR amplification was also used to isolate VSV-G FL 
with PCR introduced 5’ BamHI and 3’ XbaI sites.  Sequence specific forward (5’ CAT CGG 
GCG CGG ATC CGC CAC CAT GAA GTG CCT TTT GTA CTT AGC CTT TTT AT) and reverse 
(GAC TGC AGG CTC TAG ATT ACT TTC CAA GTC GGT TCA TCT CTA TGT CT 5’) primers 
were purchased from IDT again with a 10 base homology to vector.  The same 
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conditions for PCR amplification were used as in the PCR for truncated VSV-G except 
PFU Ultra was not used (simply out of stock), only PFU Turbo and PFU Herculase.  
pCMVDual-ZsGreen preparation 
The transfer vector (pCMVDual-ZsGreen) was designed in house by Jim 
Fornwald. The vector contains both a polyhedrin promoter and a CMV promoter.  
ZsGreen, a type of Green Fluorescence Protein (GFP), was inserted previously by Jim 
Fornwald so that it was under control of the CMV promoter (Figure 5).  In order to 
linearize pCMVDual-ZsGreen and insert truncated and FL VSV-G under the polyhedrin 
promoter, pCMVDual-ZsGreen was digested with BamHI and XbaI present in the 
Multiple Cloning Site (MCS). VSV-G must be inserted under the polyhedrin promoter so 
that it will not be expressed in mammalian cells which would interfere with downstream 
processes.  Also, VSV-G does not need to be expressed in mammalian cells; its effect is 
on the virion envelope.  
pFastBac preparation 
The vector pFastBac was also linearized using the same restriction enzymes as 
for pCMVDual-ZsGreen.  pFastBac is a traditional baculovirus vector with only the insect 
specific polyhedrin promoter and no reporter gene present (Figure 6). 3 µL of each 
vector (each in a separate reaction) were digested with 10 units each (1 µL) of BamHI 
and Xbal in the presence of 1X (4 µL) of New England BioLab’s Buffer 4 and  4ug Bovine 
Serum Albumin (BSA) (4 µL).  pFastBac-VSV-G (both full length and truncated) were 
constructed for co-transduction purposes while pCMVDual-ZsGreen -VSV-G (both full 
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length and truncated) were engineered for a single population of virus (Figure 7).  In co-
production, a mixed population of virus with and without VSV-G and/or ZsGreen is 
present but can sometimes be effective enough for transduction.  
 
Figure 5: Schematic of pCMVDual-ZsGreen (provided by Jim Fornwald). The reporter 
gene ZsGreen is driven by the mammalian cytomegalovirus (CMV) promoter. There is a 
Multiple Cloning Site (MCS) found after the polyhedrin promoter (Ppoh) to facilitate 
insertion of genes of interest. In this case, the sites BamHI and XbaI are used to insert 
VSV-G sequence. AmpR (Ampicillin) and GentR (Gentamycin) antibiotic resistant 
sequences are included for transformation and growing in E. coli competent cells.  Tn7L 
and Tn7R sites are present for BacMid production (explained later).  
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Figure 6: Schematic of pFastBac (provided by GSK in-house archive).  MCS is present 
after Ppoh for adding genes of interest.  Antibiotic resistant sites are present in the 
vector as well as Tn7L and Tn7R sites.   
 
Figure 7: Two different methods of pseudotyping. Figure A describes adding BacMam 
virus with the reporter gene ZsGreen (ZSG) and Baculovirus with VSV-G ratiometrically 
to Sf9 cells for production of CMVDual-ZsGreen-VSV-G Virus. This method produces a 
mixed population of virus with one of either genes or both. pFastBac-VSV-G was 
constructed for this.  Figure B describes inserting VSV-G and CMV-ZSG into the same 
transfer vector. This method produces one virus type creating a single virus population.  
 
Inserting Truncated and Full Length VSV-G into pFastBac 
The Quick Cloning Kit (BPS) was used to insert the VSV-G fragments into the 
pCMVDual-ZsGreen and pFastBac vectors (Figure 8). This kit utilizes a 10 bp homology 
between the fragment and the vector.  200 ng of each vector was combined with 60 ng 
of fragment with 1 µL of proprietary “Buffer A”, 1 µL of “Reagent A”, and 1X BSA and 
incubated at room temperature (220C) for 30 min.  1 µL of “Reagent B” added to 
reaction and placed on ice for 5 min.  The Quick Cloning Kit is a proprietary ligase 
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independent reaction. After the reaction, the DNA was transformed into DH5alpha E. 
coli competent cells and plated on LB-agar Ampicillin plates for selection.  All transfer 
vectors contain GentR and AmpR sites for selection and growth on antibiotic agar plates 
(Figures 9-12). 
Source: BPS Biosciences 
Figure 8: Schematic of BPS Quick Cloning Kit Protocol. Primers include a 10 base 
homology to the transfer vectors. A simple 35 min reaction with Vector, Insert, Buffer A, 
Reagent A, and BSA and subsequently Reagent B in a microcentrifuge tube is sufficient 
for incorporation of insert into vector.  
 
Identification of Positive Clones 
 Ten colonies of each construct were run in a colony PCR for identification of 
positive clones. A colony PCR uses the DNA directly from the picked colony. Reaction is 
the same as PCR amplification (Figure 4) with the initial denaturation step lasting 5 
minutes to lyse E. coli cells.   The forward primer used for PCR was specific to the vector, 
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while the reverse primer was specific to the VSV-G insert (Figure 9). Therefore, when 
run on agarose gel, only positive clones will produce a band. Final constructs have 
truncated or FL VSV-G in either pFastBac or pCMVDual-ZsGreen (Figures 10-13).    
 
Figure 9: Location of Colony PCR primers. Forward primer (green) lies in the 
polyhedrin promoter (exists in the vector). The reverse primer (red) is found 
within insert. The PCR will only produce product if insert is present because the 
reverse primer will not anneal to sequence that is not present. 
 
 
 
Figure 10: Schematic of final construct. VSV-G truncate is under control of polyhedrin 
promoter (Ppoh) and is labeled in blue. This contains gp64 short sequence (gp64SS), a 
multiple cloning site (MCS) for future insertion of other sequences of interest, a 20 
amino acid alanine spacer (A20) and the ectodomain, transmembrane domain, and C-
terminal domain (CTD) of VSV-G. ZsGreen (labeled in green) is under the control of the 
mammalian CMV promoter.  
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Figure 11:  pFastBac-VSV-G truncate. This construct does not contain reporter gene 
ZsGreen.  Truncated VSV-G has the same features as pCMVDual-ZsGreen -VSV-G 
truncate. 
 
 
Figure 12:  pCMVDual-ZsGreen VSV-G FL. Note that there is no MCS before VSV-G in this 
construct so further manipulation is not readily feasible. 
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Figure 13:  pFastBac VSV-G FL. Again, there is no MCS before VSV-G.  
 
Sequencing Confirmation of Virus Transfer Vectors 
 Sequencing oligonucleotides were designed and ordered from IDT.  Using the 
electronic predicted sequence, short oligos of 24-33 bases were chosen internally and 
flanking FL and Truncated VSV-G on both top and bottom strand of DNA (Table 1).  
Oligos are designed every 400-500 bases for assurance of complete double strand 
sequence of the insert. Sequence runs usually span between 500-800 bases. Because 
the truncated VSV-G insert is only 348 base pairs in length only vector specific primers 
were necessary for complete sequencing. Direct sequencing of each transfer vector was 
performed by another GSK group with AB v3.1 BigDye-terminator cycle sequencing kit 
(Applied Biosystems, Carlsbad, California). Each sample was amplified separately in a 
cycle sequencing reaction with 1 µL AB v3.1 BigDye-terminator cycle sequencing, 6 µL of 
deionized water, 1uL of DNA template, 1uL of primer and 1uL of 5X Sequencing Buffer 
(Applied Biosystems) for a total volume of 10 µL. Thermal cycling conditions were one 
cycle of 1 min at 96 °C, 25 cycles of 10 sec at 96 °C, 5 sec at 50 °C, 4 min at 60 °C and one 
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hold of 4 °C until ready to purify. The extension products were purified using an Edge 
DTR V3 96-Well Short Plate (Edge Biosystems, Gaithersburg, MD). The sequencing 
reactions were analyzed using a Genetic Analyzer 3730XL (Applied Biosystems).  
Primer 
Name 
Strand Sequence Size Use in vector FL or 
truncate 
pFB for 
 
Top CCGGATTATTCATACCGTCCCACC 24 pFB/pCMVDual FL/ 
truncated 
pFB rev 
 
Bottom CCTCTACAAATGTGGTATGGCTGATTATG 29 pFB/pCMVDual FL/ 
truncated 
FL VSV-G 
REV 3 
Bottom GCTTGACGGGCAATAATGGTAATTAG 26 pFB/pCMVDual FL  
FL VSV-G 
FOR 1 
Top CAGGCTTCCCTCCTCAAAGTTGTGGATATG 30 pFB/pCMVDual FL  
FL VSV-G 
REV 2 
Bottom GAGGTTAGAATCACATAGCCCTTTGACC 28 pFB/pCMVDual FL  
FL VSV-G 
FOR 2 
Top GGATCTTGGATTATTCCCTCTGCCAAGAAACC 32 pFB/pCMVDual FL  
FL VSV-G 
REV 1 
Bottom GGTAGTTCCACTGATCATTCCGACCATTC 29 pFB/pCMVDual FL  
FL VSV-G 
FOR 3 
Top GGTTGGTTCAGTAGTTGGAAAAGCTCTATTGCC 33 pFB/pCMVDual FL  
Table 1:  List of Sequencing Oligos. They are located every 400-500 bases of the insert 
on both top and bottom strands of DNA.  
 
Generation of BacMid DNA 
 The BacMid system is a site-specific transposon-mediated insertion method, 
used to facilitate production of recombinant DNA from the viral transfer vector into the 
viral genome.  After verification of desired baculovirus transfer constructs, the DNA was 
transformed into DH10Bac E. coli competent cells and streaked on DH10Bac plates (LB 
agar plates with 50 ug/mL Kanamycin, 10 ug/mL Tetracycline and 7 ug/mL Gentamycin) 
for selection and again streaked for single colonies (Figure 14).  Generation of BacMid 
DNA is based on Invitrogen’s Bac-to-Bac system (Carlsbad, CA) . DH10Bac cells contain 
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two types of plasmids: parent and helper. The parent plasmid contains Tn7R and Tn7L 
sites for transposition of gene found in the transfer vector. Each transfer vector also 
contains Tn7 sites flanking gene region (Figures 10-13) and with the assistance of the 
helper plasmid, the gene is moved from transfer vector to parent. Also, found inside the 
parent plasmid is the lac-Zα  gene. When expressed, the protein created a blue E. coli 
colony. When successful transposition occurs, this expression is disrupted creating a 
white colony. This blue/white screening aids in identification of positive colonies.  
 
 
Figure 14: BacMam/Baculovirus generation:  The schematic shows each step of 
creating a Baculovirus (or BacMam). Steps to creating virus are the same after 
generation of transfer vectors. All transfer vectors contain Tn7 sites for transposition 
into parent plasmid for BacMid DNA generation.  
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Isolation of BacMid DNA 
 BacMid DNA is isolated using a modified miniprep alkaline lysis method with 
reagents from Qiagen.  At this point all reagents are handled using sterile work 
conditions.  Three large white colonies were picked for each BacMid and inoculated in 2 
mL DH10Bac growth medium (LB broth with same antibiotic concentrations as DH10Bac 
plates) and grown at 340C overnight. Growth was transferred to 2 mL microcentrifuge 
tubes and cells were pelleted by centrifugation.  Cells were resuspended with 200 µL of 
reagent P1 and lysed with 200 µL P2. 200 µL of P3 was added then centrifuged for 10 
minutes to pellet debris. Supernatant was collected and transferred to clean tubes. 
Addition of 420 µL isopropanol precipitated BacMid DNA from supernatant. After 20 
minutes in -200C, mix was centrifuged again to pellet DNA. DNA was dried and 
resuspended in 50 µL of dH20.  
Transfection of Sf-9 cells 
Sf-9 cells were seeded into a T-25 flask at a concentration of 1x10^6 cells/mL in 3 
mL. The cells were given 30 minutes to attach to the flask. Meanwhile, 25 µL of the 
BacMid DNA was added to a transfection mix comprised of 200 µL EX-CELL 420 (JRH 
Biosciences) media and 7 µL Fugene 6 (Roche). The mix was incubated at room 
temperature for 15 min then added drop-wise directly onto the Sf-9 cells. Cells were 
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incubated at 27oC overnight with 3ml of EX-CELL 420 with 10% Heat Inactivated FBS 
added to the transfected cells  (JRH Biosciences). The flasks were incubated for an 
additional three days at 27oC before cytopathic effect occurred. Cytopathic effect is a 
clearing of cells (and when held to the light, it appears as a comet like clearing). The 
conditioned medium was harvested and centrifuged in a 15 mL conical tube to pellet 
remaining cells. The supernatant was kept and stored at 4oC in the dark. The 
supernatant is referred to as Passage 0(P0) virus.  
Generation of P1 virus 
The viruses were further amplified using fresh Sf-9 cells. Cells were seeded in 
suspension at a concentration of 8x10^5 cells/mL in 150 mL overnight at 27oC. Cells 
were infected with 1 mL of virus along with 5% heat inactivated FBS. Cells were 
monitored and counted to ensure cell growth had ceased (cells usually double in 18-24 
hours). When virus has infected cells, cells are lysed and growth of new cells is slowed or 
ceased. Three days after infection, the cells were analyzed for viability (<50%) and 
harvested in the same manner as P0 virus. The resultant P1 virus was submitted for viral 
titer.  
Virus Titration 
Viruses were titered by Don Fisher (GSK) using Invitrogen’s BaculoTiter Assay 
(Figure 15). The assay kit utilizes a stable insect cell line (Sf21) with expression of β-
lactamase reporter gene driven by a baculovirus-responsive promoter. Upon infection 
cells show a dose-dependent response in β-lactamase activity. This activity is quantified 
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by a ratiometric live-cell substrate and fluorescence that can easily be read with a 
fluorescence microplate reader.  
 
Figure 15:  Schematic of BaculoTiter assay protocol. Activity is quantified on 
fluorescent micro-plate reader.  
Source: https://commerce.invitrogen.com/index.cfm?fuseaction=viewCatalog. 
viewProductDetails&productDescription=33070  
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CHAPTER 3: Results 
Restriction Digest of truncated VSV-G from its holding vector 
After restriction digest of pZero-2-truncated VSV-G the fragment was run on an 
agarose gel for correct size identification and to separate the fragment from the pZero2 
vector. After this, it was determined that the size of the fragment was double its correct 
size of 360 base pairs (Figure 16). 
 
Figure 16:  First restriction digest of VSV-G cassette excised from pZero-2 using BamHI 
and XbaI. Lane 1: High range ladder,  Lane 2: Low range Ladder, Lanes 3&4: Restriction 
digest of pZero2-VSV-G truncate. Major band is pZERO vector. Faint band is VSV-G 
truncate shown at 800 bp, incorrect size (should be about 400 bp.) This is possibly 
because of a dimer in the commercial vector.  
 
 PCR Amplification of truncated and Full Length VSV-G 
After PCR amplification of the VSV-G truncate fragment using three different 
polymerases, it was also run on a gel for size identification. This time, the fragment was 
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the correct size for each reaction (Figure 17).  Three polymerases were used in case one 
failed, however all polymerases successfully amplified the insert and showed a 
comparable concentration of DNA.  
 
Figure 17: PCR reaction for VSV-G truncate. Two lanes for each polymerase: Lane 1:  Low 
range Ladder Lane 2: High range ladder. Lanes 3&4: PFU Turbo, Lanes 5&6 PFU 
Herculase, Lanes 7&8: PFU Ultra. All show the correct band size for VSV-G truncate.  
Also, due to the PCR, the DNA is much more concentrated for use as seen by the 
brightness of the bands.   
 
  PCR amplification was used to extract FL VSV-G from its holding vector. The 
expected size is 1.5 kb (Figure 18). FL VSV-G was amplified using PFU Turbo and PFU 
Herculase. PFU Ultra was out of stock when performing reactions and was omitted. 
Again, PFU Turbo and Herculase successfully amplified VSV-G and both with high yields.  
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Figure 18: PCR amplification of VSV-G FL. Lane 1: High Range Ladder. Lane 2: Low Range 
Ladder Lanes 3&4: VSV-G FL using PFU Turbo (size as expected) Lanes 6&7: VSV-G FL 
using PFU Herculase (size as expected).  
 
Restriction Digest of pFastBac and pCMVDual-ZsGreen 
The transfer vectors pFastBac and pCMVDual-ZsGreen were successfully digested 
with enzymes BamHI and XbaI (Figure 19). The digest of pFastBac is less concentrated 
that that of pCMVDual-ZsGreen.  
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Figure 19: Restriction Digest of pFastBac and pCMVDual-ZsGreen.  Lane 1: High Range 
Ladder. Lane 2: Low Range Ladder. Lane 3&4: Digestion of pFastBac at the correct size of 
~4000 bp. Lane 5&6: Digestion of pCMVDual-ZsGreen at the correct size of ~7000 bp.  
 
Colony PCR for pFastBac-VSV-G truncate and Full Length VSV-G 
As described previously, a Colony PCR was used to identify positive clones. Of 11 
colonies picked for PCR, one colony (clone 7) was a positive clone for pFastBac-VSV-G 
truncate (Figure 20).   Smaller bands are residual primers left from the reaction. The 
colony PCR from pFastBac-VSV-G FL produced one positive clone.  
The 48 colonies were picked for the colony PCR of pFastBac-VSV-G FL. Of the 48 
colonies, only 1 (Colony 16) presented the correct size band (Figure 21).  
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Figure 20: Colony PCR of pFastBac-VSV-G truncate. Lane 1: Low range ladder. Lanes 2-
12: Colony PCR amplification clones.  Forward insert VSV-G truncate primer and reverse 
pFastBac specific primer were used to amplify regions of positive clones. Lane 6 contains 
one positive clone. 
 
 
Figure 21: Colony PCR of pFastBac-VSV-G FL on 48 well agarose gel. Lanes 1-24 shown. 
Lane LL: Low Range ladder. Lane HL High Range Ladder.   Lanes 1-24: Colonies picked for 
PCR amplification. Lane 16 contains positive clone. Low bands are residual primers.  
 
Colony PCR for pCMVDual ZsGreen-truncate VSV-G and Full Length VSV-G 
The colony PCR for pCMVDual ZsGreen- VSV-G FL produced two positive colonies 
as shown in Figure 22. For pCMVDual ZsGreen- VSV-G truncate, the colony PCR 
produced many undesirable bands in the majority of lanes. Of the 48 colonies screened, 
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only one contained the correct size band (Figure 23). This could be due to mutations in 
those colonies or mis-priming of the primers that were used for the colony PCR.  
 
Figure 22: Colony PCR of pCMVDual-VSV-G FL. Lane 1: Low range ladder. Lanes 2-12: 
Colony PCR amplification clones.  Forward VSV-G specific primer and a reverse vector 
specific primer were used to amplify regions of positive clones. Lanes 9 and 12 contain 
positive clones. 
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Figure 23: Colony PCR of pCMVDual-VSV-G truncate on 48 well agarose gel. Lanes 1-24 
shown Lanes L: Low range ladder. Lanes 1-24: Colony PCR amplification clones.  Forward 
VSV-G specific primer and a reverse vector specific primer were used to amplify regions 
of positive clones. Lane 8: Only clone with major band at correct size indicating a 
positive clone.  Larger bands seen could be due to mutations or mis-priming of the 
primers chosen.  
 
At least one colony from each vector was grown and midiprepped for sequence 
analysis.  It was grown up in LB media with antibiotic Ampicillin for sequence analysis.  
Sequencing of transfer vectors 
Sequence analysis of each vector showed successful insertion of VSV-G.  Figure 24 
shows an example of sequence analysis of pFastBac-VSV-G truncate.  
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Figure 24:  Sequence Analysis of pFastBac-VSV-G truncate. Analysis shows 100% correct 
sequence of the VSV-G insert.  One DNA sequence read is shown to illustrate peaks in 
the read. 
 
Viral Titer of Viruses 
A viral titer above 1x108 pfu/mL is acceptable at GSK for further studies. All 
viruses that were produced were above that threshold and have been archived for use 
of all GSK scientists. These viruses will be used to transduce cell lines that have not 
expressed genes well in the past. 
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Virus Titer Acceptable 
FastBac-VSV-G truncate 1.89*10
8
 pfu/mL Yes 
FastBac-VSV-G FL 1.48*10
8
 pfu/mL Yes 
CMVdual-ZsGreen-VSV-G 
truncate 
1.46*10
8
 pfu/mL Yes 
CMVdual-ZsGreen-VSV-G FL 3.28*10
8
 pfu/mL Yes 
Table 2:  List of Titers of Produced Viruses. All viruses possess a titer high enough for 
future experiments.  
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CHAPTER 4: Discussion 
  In conclusion, I was able to insert truncated VSV-G and FL DNA sequence into 
pFastBac and pCMVDual-Zsgreen transfer vectors and create viable BacMam viruses for 
expression in mammalian cells. This was confirmed by the titer of the virus.  Because of 
their pseudotyping elements, these BacMams should be more effective than standard 
BacMam viruses.  
The gene of interest VSV-G (truncated) was ordered from an outside company in 
its own holding vector. After numerous attempts to isolate it with restriction enzyme 
digest, it was found to be the incorrect size: exactly twice the size it should have been. 
This implies that a dimer construct was delivered. Due to this, another approach had to 
be used to obtain the VSV-G gene.  PCR was used to amplify the gene and the product 
was run on an agarose gel to extract the appropriate sized DNA.  
The PCR amplification was performed using three different polymerases. With 
some templates, one polymerase works better than others. It is standard practice to run 
all three polymerases for those cases. As it was seen in Figures 17 and 18, the yield was 
comparable and very high for each of the three polymerases. 
The restriction digests of pFastBac and pCMVDual-ZsGreen show significantly 
different concentrations of cut vector. The cause of this was the amount of starting 
vector. pFastBac was provided at a lower concentration than pCMVDual-ZsGreen (3ul 
was used in the digestion).  This should have been normalized so that the starting 
concentration was the same.  However, the digestion was successful for both vectors.  
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When the constructs that were to be generated were designed, a multiple 
cloning site (MCS) was incorporated for facile insertion of other future genes of interest. 
The three enzymes in the MCS were StuI/SpeI/EcoRI.  This design was used for both 
pCMVDual-ZsGreen and pFastBac. After successfully inserting the VSV-G synthetic gene 
into these vectors, it was realized that the pCMVDual-ZsGreen vector contained the cut 
sites SpeI and EcoRI internally and therefore the MCS would be unusable. The MCS for 
this construct will need to be redesigned and inserted using a site directed mutagenesis 
protocol. This could have been avoided by double checking the design in each construct 
before starting the wet work.   
In all, the BPS Quick Cloning Kit was a good approach to inserting the VSV-G 
genes into the transfer vectors. However, the efficiency of the kit is typically 90% or 
higher. Results for this project were 2%-16%. This is most likely due to the design of 
amplification primers. The protocol suggests a 10 base homology to the vector 
sequence. However, in future applications, a higher efficiency of positive clones were 
observed with a vector homology of 15-18 bases.  
The set of pseudotyping viruses will be used for transduction efficiency 
experiments. Because of the success of VSV-G pseudotyping in retroviruses10 and other 
baculoviruses3,21  reported in literature, it is anticipated that the viruses will effectively 
transduce cell lines of interest. Our group has determined through literature and 
personal experiences a collection of eight cell lines that have been difficult to transduce 
using the standard BacMam virus approach (Table 3).  
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Cell Line Description Reference 
THP-1 Human monocyte acute Monocytic leukemia Condreay et al. 127-32
12
 
SK-BR-3 Human Breast Adenocarcinoma  lab observance 
HEPM human embryonic palatal mesenchyme lab observance 
U937 Human monocyte histiocytic lymphoma  Condreay et al. 127-32
12
 
K562 Human lymphoblast chronic myelogenous leukemia  Condreay et al. 127-32
12
 
Raw264.7 Abelson murine leukemia virus-induced tumor macrophage Condreay et al. 127-32
12
 
LCL-cm B lymphocyte  Cheng et al. 1612-18
11
 
Raji Burkitt’s lymphoma Cheng et al. 1612-18
11
 
Table 3:  Cell lines of interest. These 8 cell lines have been chosen due to literature or 
lab group experiences that they do not transduce efficiently using standard BacMam 
virus.  They will be transduced with the pseudotyped viruses in hopes of higher gene 
expression.   
 
  There are also some modifications to the VSV-G BacMam that could be done that 
may increase the efficiency of transduction and targeting cancer cell lines. There are a 
set of tumor homing peptides have been identified to specifically target tumor 
vasculature 30. Lyp-1, F3 and CGKRK have been seen to home to the neovasculature or 
lymphatics of lab created tumors. Using the MCS engineered into the BacMam transfer 
vectors, we hope to insert these tumor homing peptides into the vectors for more 
experiments.  
If we are able to successfully transduce these cell lines, we will be able to open 
another door in cancer research. With cells that are more physiologically relevant, 
screening efforts may be able to bring about better compounds that can withstand 
clinical trials. Attrition rates of  pharmaceutical compounds are near 90% and there is a 
huge need to reduce this number23. There are several ways that companies can attempt 
to lower this number but more physiological in vitro primary screens may be an early 
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pipeline remedy. Not only will this be helpful from a business aspect, but also for the 
patients that we are hoping to treat and cure.  Although this may be a small step, it 
could be one step closer to curing cancer.   
 With more modifications, VSV-G pseudotyped BacMams could possibly be used 
in the future for human gene therapy. Because BacMam viruses cannot replicate in 
human cells but can transiently express genes, they would be safer than adenoviruses or 
other current methods of human gene delivery.  Baculoviruses have been used to 
effectively treat tumors in animal models49 and perhaps could translate into a successful 
model in humans.   
  
40 
 
 
Reference List 
 
 1 R. Ames, et al., "Heterologous expression of G protein-coupled receptors in U-2 OS 
osteosarcoma cells," Receptors. Channels 10(3-4), 117 (2004). 
Ref Type: Journal 
 2 M. D. Ayres, et al., "The complete DNA sequence of Autographa californica nuclear 
polyhedrosis virus," Virology 202(2), 586 (1994). 
Ref Type: Journal 
 3 J. Barsoum, et al., "Efficient transduction of mammalian cells by a recombinant 
baculovirus having the vesicular stomatitis virus G glycoprotein," Hum. Gene Ther. 
8(17), 2011 (1997). 
Ref Type: Journal 
 4 G. W. Blissard and G. F. Rohrmann, "Location, sequence, transcriptional mapping, and 
temporal expression of the gp64 envelope glycoprotein gene of the Orgyia 
pseudotsugata multicapsid nuclear polyhedrosis virus," Virology 170(2), 537 
(1989). 
Ref Type: Journal 
 5 G. W. Blissard and J. R. Wenz, "Baculovirus gp64 envelope glycoprotein is sufficient to 
mediate pH-dependent membrane fusion," J. Virol. 66(11), 6829 (1992). 
Ref Type: Journal 
 6 F. M. Boyce and N. L. Bucher, "Baculovirus-mediated gene transfer into mammalian cells," 
Proc. Natl. Acad. Sci. U. S. A 93(6), 2348 (1996). 
Ref Type: Journal 
 7 A. Braun, "Biosafety in handling gene transfer vectors," Curr. Protoc. Hum. Genet. Chapter 
12, Unit (2006). 
Ref Type: Journal 
 8 S. C. Braunagel, et al., "Identification and analysis of an Autographa californica nuclear 
polyhedrosis virus structural protein of the occlusion-derived virus envelope: 
ODV-E56," Virology 217(1), 97 (1996). 
Ref Type: Journal 
 9 S. C. Braunagel and M. D. Summers, "Autographa californica nuclear polyhedrosis virus, 
PDV, and ECV viral envelopes and nucleocapsids: structural proteins, antigens, 
lipid and fatty acid profiles," Virology 202(1), 315 (1994). 
Ref Type: Journal 
 10 J. C. Burns, et al., "Vesicular stomatitis virus G glycoprotein pseudotyped retroviral 
vectors: concentration to very high titer and efficient gene transfer into 
mammalian and nonmammalian cells," Proc. Natl. Acad. Sci. U. S. A 90(17), 8033 
41 
 
 
(1993). 
Ref Type: Journal 
 11 T. Cheng, et al., "A rapid and efficient method to express target genes in mammalian cells 
by baculovirus," World J. Gastroenterol. 10(11), 1612 (2004). 
Ref Type: Journal 
 12 J. P. Condreay and T. A. Kost, "Baculovirus expression vectors for insect and mammalian 
cells," Curr. Drug Targets. 8(10), 1126 (2007). 
Ref Type: Journal 
 13 J. P. Condreay, et al., "Transient and stable gene expression in mammalian cells 
transduced with a recombinant baculovirus vector," Proc. Natl. Acad. Sci. U. S. A 
96(1), 127 (1999). 
Ref Type: Journal 
 14 E. K. Engelhard, et al., "The insect tracheal system: a conduit for the systemic spread of 
Autographa californica M nuclear polyhedrosis virus," Proc. Natl. Acad. Sci. U. S. A 
91(8), 3224 (1994). 
Ref Type: Journal 
 15 P. F. Entwistle, P. H. Adams, and H. F. Evans, "Epizootiology of a nuclear polyhedrosis virus 
in European spruce sawfly (Gilpinia hercyniae): the rate of passage of infective 
virus through the gut of birds during cage tests," J. Invertebr. Pathol. 31(3), 307 
(1978). 
Ref Type: Journal 
 16 W. J. Ernst, R. M. Grabherr, and H. W. Katinger, "Direct cloning into the Autographa 
californica nuclear polyhedrosis virus for generation of recombinant 
baculoviruses," Nucleic Acids Res. 22(14), 2855 (1994). 
Ref Type: Journal 
 17 J. A. Fornwald, et al., "Gene expression in mammalian cells using BacMam, a modified 
baculovirus system," Methods Mol. Biol. 388, 95 (2007). 
Ref Type: Journal 
 18 R. E. Hawtin, et al., "Liquefaction of Autographa californica nucleopolyhedrovirus-infected 
insects is dependent on the integrity of virus-encoded chitinase and cathepsin 
genes," Virology 238(2), 243 (1997). 
Ref Type: Journal 
 19 C. Hofmann, et al., "Efficient gene transfer into human hepatocytes by baculovirus 
vectors," Proc. Natl. Acad. Sci. U. S. A 92(22), 10099 (1995). 
Ref Type: Journal 
 20 H. M. Horton and J. P. Burand, "Saturable attachment sites for polyhedron-derived 
baculovirus on insect cells and evidence for entry via direct membrane fusion," J. 
Virol. 67(4), 1860 (1993). 
Ref Type: Journal 
42 
 
 
 21 M. U. Kaikkonen, et al., "Truncated vesicular stomatitis virus G protein improves 
baculovirus transduction efficiency in vitro and in vivo," Gene Ther. 13(4), 304 
(2006). 
Ref Type: Journal 
 22 B. J. Kelly, L. A. King, and R. D. Possee, "Introduction to baculovirus molecular biology," 
Methods Mol. Biol. 388, 25 (2007). 
Ref Type: Journal 
 23 I. Kola and J. Landis, "Can the pharmaceutical industry reduce attrition rates?," Nat. Rev. 
Drug Discov. 3(8), 711 (2004). 
Ref Type: Journal 
 24 T. A. Kost and J. P. Condreay, "Recombinant baculoviruses as mammalian cell gene-
delivery vectors," Trends Biotechnol. 20(4), 173 (2002). 
Ref Type: Journal 
 25 T. A. Kost, J. P. Condreay, and D. L. Jarvis, "Baculovirus as versatile vectors for protein 
expression in insect and mammalian cells," Nat. Biotechnol. 23(5), 567 (2005). 
Ref Type: Journal 
 26 J. Kuzio, R. Jaques, and P. Faulkner, "Identification of p74, a gene essential for virulence of 
baculovirus occlusion bodies," Virology 173(2), 759 (1989). 
Ref Type: Journal 
 27 V. A. Luckow, et al., "Efficient generation of infectious recombinant baculoviruses by site-
specific transposon-mediated insertion of foreign genes into a baculovirus 
genome propagated in Escherichia coli," J. Virol. 67(8), 4566 (1993). 
Ref Type: Journal 
 28 L. Ma, et al., "Baculovirus-mediated gene transfer into pancreatic islet cells," Diabetes 
49(12), 1986 (2000). 
Ref Type: Journal 
 29 L. Ma, et al., "Baculovirus-mediated gene transfer into pancreatic islet cells," Diabetes 
49(12), 1986 (2000). 
Ref Type: Journal 
 30 A. R. Makela, et al., "Enhanced baculovirus-mediated transduction of human cancer cells 
by tumor-homing peptides," J. Virol. 80(13), 6603 (2006). 
Ref Type: Journal 
 31 D. R. O'Reilly, "Use of baculovirus expression vectors," Methods Mol. Biol. 62, 235 (1997). 
Ref Type: Journal 
 32 A. G. Oomens and G. W. Blissard, "Requirement for GP64 to drive efficient budding of 
Autographa californica multicapsid nucleopolyhedrovirus," Virology 254(2), 297 
(1999). 
Ref Type: Journal 
43 
 
 
 33 M. N. Pearson, R. L. Russell, and G. F. Rohrmann, "Characterization of a baculovirus-
encoded protein that is associated with infected-cell membranes and budded 
virions," Virology 291(1), 22 (2001). 
Ref Type: Journal 
 34 R. D. Possee and L. A. King, "Baculovirus transfer vectors," Methods Mol. Biol. 388, 55 
(2007). 
Ref Type: Journal 
 35 L. Ramos, et al., "Rapid expression of recombinant proteins in modified CHO cells using 
the baculovirus system," Cytotechnology 38(1-3), 37 (2002). 
Ref Type: Journal 
 36 C. S. Robison and M. A. Whitt, "The membrane-proximal stem region of vesicular 
stomatitis virus G protein confers efficient virus assembly," J. Virol. 74(5), 2239 
(2000). 
Ref Type: Journal 
 37 C. S. Robison and M. A. Whitt, "The membrane-proximal stem region of vesicular 
stomatitis virus G protein confers efficient virus assembly," J. Virol. 74(5), 2239 
(2000). 
Ref Type: Journal 
 38 G. F Rohrmann, "Baculovirus Molecular Biology,"in (NCBI, Bethesda (MD)  National Library 
of Medicine (US), 2008). 
 39 D. A. Sanders, "No false start for novel pseudotyped vectors," Curr. Opin. Biotechnol. 
13(5), 437 (2002). 
Ref Type: Journal 
 40 I. Shoji, et al., "Efficient gene transfer into various mammalian cells, including non-hepatic 
cells, by baculovirus vectors," J. Gen. Virol. 78 ( Pt 10), 2657 (1997). 
Ref Type: Journal 
 41 I. Shoji, et al., "Efficient gene transfer into various mammalian cells, including non-hepatic 
cells, by baculovirus vectors," J. Gen. Virol. 78 ( Pt 10), 2657 (1997). 
Ref Type: Journal 
 42 G. E. Smith, M. J. Fraser, and M. D. Summers, "Molecular Engineering of the Autographa 
californica Nuclear Polyhedrosis Virus Genome: Deletion Mutations Within the 
Polyhedrin Gene," J. Virol. 46(2), 584 (1983). 
Ref Type: Journal 
 43 G. E. Smith, M. D. Summers, and M. J. Fraser, "Production of human beta interferon in 
insect cells infected with a baculovirus expression vector," Mol. Cell Biol. 3(12), 
2156 (1983). 
Ref Type: Journal 
44 
 
 
 44 H. Tani, et al., "Characterization of cell-surface determinants important for baculovirus 
infection," Virology 279(1), 343 (2001). 
Ref Type: Journal 
 45 D. Theilmann, et al., "Baculoviridae,"in Virus Taxonomy: Eighth report of the International 
commitee on Taxonomy of Virsuses.,(Elsevier Academic press, New York, NY, 
2010), pp.177-185. 
 46 J. L. Vaughn, et al., "The establishment of two cell lines from the insect Spodoptera 
frugiperda (Lepidoptera; Noctuidae)," In Vitro 13(4), 213 (1977). 
Ref Type: Journal 
 47 L. E. Volkman, "Occluded and Budded Autographa californica Nuclear Polyhedrosis Virus: 
Immunological Relatedness of Structural Proteins," J. Virol. 46(1), 221 (1983). 
Ref Type: Journal 
 48 J. Wang, et al., "[Experimental study of baculovirus-mediated transfection of spiral 
ganglion cells in rats]," Zhonghua Er. Bi Yan. Hou Tou. Jing. Wai Ke. Za Zhi. 42(12), 
939 (2007). 
Ref Type: Journal 
 49 S. Wang and G. Balasundaram, "Potential Cancer Gene Therapy by Baculoviral 
Transduction," Curr. Gene Ther.  (2010). 
Ref Type: Journal 
 50 P. M. Zanotto, B. D. Kessing, and J. E. Maruniak, "Phylogenetic interrelationships among 
baculoviruses: evolutionary rates and host associations," J. Invertebr. Pathol. 
62(2), 147 (1993). 
Ref Type: Journal 
 
 
